Global Shigella Vaccines Market
Global Shigella Vaccines Market

Shigella Vaccines Comprehensive Study by Application (Hospitals, Clinics, Academic and Research, Others), Species (Shigella Sonnei, Shigella Flexneri, Shigella Boydii, Shigella Dysenteriae) Players and Region - Global Market Outlook to 2026

Shigella Vaccines Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 216 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Shigella Vaccines Market Overview:
Shigellosis is an infectious disease caused by a group of bacteria called Shigella. Shigella is a gram-negative pathogenic enterobacterium that causes severe diarrhea and dysentery in humans. Symptoms associated with Shigella infection include fever, stomach pain, tenesmus, watery diarrhea, vomiting, dehydration, and convulsions.

Growth Drivers
  • Increase in Incidence of Shigella Infection across the Globe
  • Lack of Vaccination for Shigella Infection

Market Trends
  • Ongoing Clinical Trials and Studies on Development of Treatment for Combating Shigella Species

Roadblocks
  • High Cost Associated With Storage And Supply Of Vaccines

Opportunities
  • Rise in Research & Development
  • Increasing Immunization Programs And Government Initiatives

Challenges
  • Lack of Awareness of the Harmful Effects of Shigella


Competitive Landscape:
The global Shigella Vaccines market is fragmented and the leading pharmaceutical companies are working on their research and development team to clear all the clinical trials and get approval from the FDA to launch its vaccines.
Some of the key players profiled in the report are MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd. (United States), Novartis (Switzerland) and GlaxoSmithKline plc (United Kingdom). Considering Market by Species, the sub-segment i.e. Shigella Sonnei will boost the Shigella Vaccines market.

Latest Market Insights:
In Oct 2019, The European Vaccine Initiative (EVI) and Hilleman Laboratories, announced partnership for the development of new shigella vaccine.

In Sept 2019, LimmaTech Biologics AG and GlaxoSmithKline plc., collaboratively initiated Phase I/II clinical trial of 4-valent candidate vaccine in Kenya to prevent diarrheal disease cause due to Shigella in the developing economies.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Shigella Vaccines market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Shigella Vaccines market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Shigella Vaccines Manufacturers, Shigella Vaccines Suppliers, Raw Material Suppliers, Research and Development Organization, Potential Investors and Government Agencies.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Application
  • Hospitals
  • Clinics
  • Academic and Research
  • Others
By Species
  • Shigella Sonnei
  • Shigella Flexneri
  • Shigella Boydii
  • Shigella Dysenteriae

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Incidence of Shigella Infection across the Globe
      • 3.2.2. Lack of Vaccination for Shigella Infection
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness of the Harmful Effects of Shigella
    • 3.4. Market Trends
      • 3.4.1. Ongoing Clinical Trials and Studies on Development of Treatment for Combating Shigella Species
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Shigella Vaccines, by Application, Species and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Shigella Vaccines (Value)
      • 5.2.1. Global Shigella Vaccines by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Academic and Research
        • 5.2.1.4. Others
      • 5.2.2. Global Shigella Vaccines by: Species (Value)
        • 5.2.2.1. Shigella Sonnei
        • 5.2.2.2. Shigella Flexneri
        • 5.2.2.3. Shigella Boydii
        • 5.2.2.4. Shigella Dysenteriae
      • 5.2.3. Global Shigella Vaccines Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Shigella Vaccines (Price)
  • 6. Shigella Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
  • 7. Global Shigella Vaccines Sale, by Application, Species and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Shigella Vaccines (Value)
      • 7.2.1. Global Shigella Vaccines by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Academic and Research
        • 7.2.1.4. Others
      • 7.2.2. Global Shigella Vaccines by: Species (Value)
        • 7.2.2.1. Shigella Sonnei
        • 7.2.2.2. Shigella Flexneri
        • 7.2.2.3. Shigella Boydii
        • 7.2.2.4. Shigella Dysenteriae
      • 7.2.3. Global Shigella Vaccines Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Shigella Vaccines (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Shigella Vaccines: by Application(USD Million)
  • Table 2. Shigella Vaccines Hospitals , by Region USD Million (2015-2020)
  • Table 3. Shigella Vaccines Clinics , by Region USD Million (2015-2020)
  • Table 4. Shigella Vaccines Academic and Research , by Region USD Million (2015-2020)
  • Table 5. Shigella Vaccines Others , by Region USD Million (2015-2020)
  • Table 6. Shigella Vaccines: by Species(USD Million)
  • Table 7. Shigella Vaccines Shigella Sonnei , by Region USD Million (2015-2020)
  • Table 8. Shigella Vaccines Shigella Flexneri , by Region USD Million (2015-2020)
  • Table 9. Shigella Vaccines Shigella Boydii , by Region USD Million (2015-2020)
  • Table 10. Shigella Vaccines Shigella Dysenteriae , by Region USD Million (2015-2020)
  • Table 11. South America Shigella Vaccines, by Country USD Million (2015-2020)
  • Table 12. South America Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 13. South America Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 14. Brazil Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 15. Brazil Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 16. Argentina Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 17. Argentina Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 18. Rest of South America Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 19. Rest of South America Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 20. Asia Pacific Shigella Vaccines, by Country USD Million (2015-2020)
  • Table 21. Asia Pacific Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 22. Asia Pacific Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 23. China Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 24. China Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 25. Japan Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 26. Japan Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 27. India Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 28. India Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 29. South Korea Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 30. South Korea Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 31. Taiwan Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 32. Taiwan Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 33. Australia Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 34. Australia Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 35. Rest of Asia-Pacific Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 36. Rest of Asia-Pacific Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 37. Europe Shigella Vaccines, by Country USD Million (2015-2020)
  • Table 38. Europe Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 39. Europe Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 40. Germany Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 41. Germany Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 42. France Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 43. France Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 44. Italy Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 45. Italy Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 46. United Kingdom Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 47. United Kingdom Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 48. Netherlands Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 49. Netherlands Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 50. Rest of Europe Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 51. Rest of Europe Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 52. MEA Shigella Vaccines, by Country USD Million (2015-2020)
  • Table 53. MEA Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 54. MEA Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 55. Middle East Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 56. Middle East Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 57. Africa Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 58. Africa Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 59. North America Shigella Vaccines, by Country USD Million (2015-2020)
  • Table 60. North America Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 61. North America Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 62. United States Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 63. United States Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 64. Canada Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 65. Canada Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 66. Mexico Shigella Vaccines, by Application USD Million (2015-2020)
  • Table 67. Mexico Shigella Vaccines, by Species USD Million (2015-2020)
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Shigella Vaccines: by Application(USD Million)
  • Table 72. Shigella Vaccines Hospitals , by Region USD Million (2021-2026)
  • Table 73. Shigella Vaccines Clinics , by Region USD Million (2021-2026)
  • Table 74. Shigella Vaccines Academic and Research , by Region USD Million (2021-2026)
  • Table 75. Shigella Vaccines Others , by Region USD Million (2021-2026)
  • Table 76. Shigella Vaccines: by Species(USD Million)
  • Table 77. Shigella Vaccines Shigella Sonnei , by Region USD Million (2021-2026)
  • Table 78. Shigella Vaccines Shigella Flexneri , by Region USD Million (2021-2026)
  • Table 79. Shigella Vaccines Shigella Boydii , by Region USD Million (2021-2026)
  • Table 80. Shigella Vaccines Shigella Dysenteriae , by Region USD Million (2021-2026)
  • Table 81. South America Shigella Vaccines, by Country USD Million (2021-2026)
  • Table 82. South America Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 83. South America Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 84. Brazil Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 85. Brazil Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 86. Argentina Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 87. Argentina Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 88. Rest of South America Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 89. Rest of South America Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 90. Asia Pacific Shigella Vaccines, by Country USD Million (2021-2026)
  • Table 91. Asia Pacific Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 92. Asia Pacific Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 93. China Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 94. China Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 95. Japan Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 96. Japan Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 97. India Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 98. India Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 99. South Korea Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 100. South Korea Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 101. Taiwan Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 102. Taiwan Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 103. Australia Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 104. Australia Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 105. Rest of Asia-Pacific Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 106. Rest of Asia-Pacific Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 107. Europe Shigella Vaccines, by Country USD Million (2021-2026)
  • Table 108. Europe Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 109. Europe Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 110. Germany Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 111. Germany Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 112. France Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 113. France Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 114. Italy Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 115. Italy Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 116. United Kingdom Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 117. United Kingdom Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 118. Netherlands Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 119. Netherlands Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 120. Rest of Europe Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 121. Rest of Europe Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 122. MEA Shigella Vaccines, by Country USD Million (2021-2026)
  • Table 123. MEA Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 124. MEA Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 125. Middle East Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 126. Middle East Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 127. Africa Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 128. Africa Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 129. North America Shigella Vaccines, by Country USD Million (2021-2026)
  • Table 130. North America Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 131. North America Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 132. United States Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 133. United States Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 134. Canada Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 135. Canada Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 136. Mexico Shigella Vaccines, by Application USD Million (2021-2026)
  • Table 137. Mexico Shigella Vaccines, by Species USD Million (2021-2026)
  • Table 138. Research Programs/Design for This Report
  • Table 139. Key Data Information from Secondary Sources
  • Table 140. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Shigella Vaccines: by Application USD Million (2015-2020)
  • Figure 5. Global Shigella Vaccines: by Species USD Million (2015-2020)
  • Figure 6. South America Shigella Vaccines Share (%), by Country
  • Figure 7. Asia Pacific Shigella Vaccines Share (%), by Country
  • Figure 8. Europe Shigella Vaccines Share (%), by Country
  • Figure 9. MEA Shigella Vaccines Share (%), by Country
  • Figure 10. North America Shigella Vaccines Share (%), by Country
  • Figure 11. Global Shigella Vaccines share by Players 2020 (%)
  • Figure 12. BCG Matrix for key Companies
  • Figure 13. MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 14. MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd. (United States) Revenue: by Geography 2020
  • Figure 15. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 16. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 17. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Global Shigella Vaccines: by Application USD Million (2021-2026)
  • Figure 20. Global Shigella Vaccines: by Species USD Million (2021-2026)
  • Figure 21. South America Shigella Vaccines Share (%), by Country
  • Figure 22. Asia Pacific Shigella Vaccines Share (%), by Country
  • Figure 23. Europe Shigella Vaccines Share (%), by Country
  • Figure 24. MEA Shigella Vaccines Share (%), by Country
  • Figure 25. North America Shigella Vaccines Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd. (United States)
  • Novartis (Switzerland)
  • GlaxoSmithKline plc (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation